<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1367D45-734D-4891-9671-3C7C7C31D0A0"><gtr:id>D1367D45-734D-4891-9671-3C7C7C31D0A0</gtr:id><gtr:name>UCB Pharma</gtr:name><gtr:address><gtr:line1>Researchdreef 60</gtr:line1><gtr:line2>Allee de la Recherche 60</gtr:line2><gtr:postCode>B-1070</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:department>Life Sciences</gtr:department><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name><gtr:address><gtr:line1>BBSRC</gtr:line1><gtr:line2>Polaris House</gtr:line2><gtr:line3>North Star Avenue</gtr:line3><gtr:line4>Swindon</gtr:line4><gtr:postCode>SN2 1UH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>CO_FUNDER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1367D45-734D-4891-9671-3C7C7C31D0A0"><gtr:id>D1367D45-734D-4891-9671-3C7C7C31D0A0</gtr:id><gtr:name>UCB Pharma</gtr:name><gtr:address><gtr:line1>Researchdreef 60</gtr:line1><gtr:line2>Allee de la Recherche 60</gtr:line2><gtr:postCode>B-1070</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/32C8D31C-8EFC-49FE-8D77-19CC2862FEF3"><gtr:id>32C8D31C-8EFC-49FE-8D77-19CC2862FEF3</gtr:id><gtr:firstName>Ewan</gtr:firstName><gtr:otherNames>William</gtr:otherNames><gtr:surname>Blanch</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=EP%2FF007922%2F1"><gtr:id>F3E0D633-D3AE-475D-8E91-01C8E695904B</gtr:id><gtr:title>SHEAR INDUCED DENATURATION OF PROTEINS</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>EP/F007922/1</gtr:grantReference><gtr:abstractText>Proteins are fundamentally important molecules crucial for life and are now becoming widely used in industrial and medical applications. The protein drug industry alone is worth $US300billion per year and is growing quickly. Proteins are highly complex polymers and they have to fold into their correct structures to function effectively. This is not simple and the importance of protein folding has been long recognised and has led to decades of research into protein unfolding (or protein denaturation), with spin offs including medical applications (unfolded proteins can cause deadly diseases such as Alzheimer's and Parkinson's) and scientific technologies (protein unfolding tools are routinely used in biology and chemistry).Although protein unfolding by chemical and thermal means are areas of intensive research, and now mechanical unfolding is being utilised as a new tool in nanobioengineering, virtually nothing is known about unfolding by shear forces in fluids. Any new tool for controlling protein structure and unfolding will be a major breakthrough and the possibility of doing this using fluids (the natural environment for most proteins and most stages of protein preparation in industry), makes shear-flow an incredibly promising tool. However, we must discover the natural laws governing this phenomenon and develop the practical tools to measure and control shear-induced unfolding before we can make use of it.We will conduct the most comprehensive examination of the effects of shear flow on protein structure yet attempted, covering a diverse range of proteins of different shapes and stabilities, investigate the effects of experimental conditions and solvent properties, and use far more sensitive tools than have previously been brought to this problem. Our aim is to not only identify which proteins do or do not undergo unfolding under shear, but to identify and quantify which parts of the protein structure change (this is more physiologically important than just saying a protein does or doesn't unfold), learn the mechanisms of how shear-induced denaturation occurs and develop the methods to control and manipulate protein unfolding. This study will also involve the first comprehensive analysis of laminar and shear flow parameters in relation to proteins, which is required to obtain a true mechanistic understanding of the process.First, we will characterise and quantify the shear parameters of the flow cells to be used (both macro- and micro-fluidic devices) and then identify which proteins, from a widely varied set of targets, do or do not unfold in fluid flows. Different proteins can have greatly different structures and stabilities and it is likely that some proteins will not unfold under our experimental conditions, some will unfold, while others may need assistance to unfold by controlling experimental parameters (pH, viscosity etc.). It will be important to examine a number of very different proteins with different shapes and inherent stabilities to identify general trends or rules, and to identify favourable targets for the second phase of the project.We will then conduct more intensive studies for those proteins found to unfold under shear, with the aim of determining which parts of the protein structure change (which is more important than just knowing if the protein unfolds or not), quantifying these changes, detailing the mechanisms responsible and learning how to manipultae protein unfolding by controlling the solution characteristics (flow rate, viscosity, pH, chemical additives). In this way we will learn which types of proteins are most susceptible to shear flows and why, and we will develop the tools and techniques to control shear induced denaturation, making it a new addition to the protein engineering toolkit.</gtr:abstractText><gtr:fund><gtr:end>2011-05-12</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name></gtr:funder><gtr:start>2007-11-13</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>323229</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>AstraZeneca</gtr:description><gtr:id>E4360D77-FB64-47A3-BE5B-3A66A5669CF1</gtr:id><gtr:impact>None yet as project is just starting</gtr:impact><gtr:outcomeId>545ea424be5de5.28619091-1</gtr:outcomeId><gtr:partnerContribution>Industry-funded stuentship and training of student in biotechnology</gtr:partnerContribution><gtr:piContribution>Cosupervising Industry CASE-funded student supplied by AstraZeneca, including training and supervision</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>UCB Pharma</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UCB Pharma</gtr:description><gtr:id>B2551F18-8E5F-46E4-A7FC-702BE62C508B</gtr:id><gtr:impact>Not yet as just starting</gtr:impact><gtr:outcomeId>545ea519aef610.03705091-1</gtr:outcomeId><gtr:partnerContribution>Sponsorship of CASE studentship
Training of student in biotechnology</gtr:partnerContribution><gtr:piContribution>Cosupervise BBSRC-funded CASE studentship</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>King's College London</gtr:description><gtr:id>BAF48ECE-6DC5-4CDE-BDE6-BC9ECD15B0C1</gtr:id><gtr:outcomeId>b9c5f7f6b9c5f80a-1</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CASE-funded Doctoral Training Account</gtr:description><gtr:end>2018-08-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/L014874/1</gtr:fundingRef><gtr:id>8C1B4750-BDE9-44C8-9039-072A47EA3C73</gtr:id><gtr:outcomeId>545e6fc09e9fd0.36696012</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CASE-funded Doctoral Training Account</gtr:description><gtr:end>2018-08-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/L014734/1</gtr:fundingRef><gtr:id>21FFE75D-76A2-4ECE-B484-AB0F8934CF50</gtr:id><gtr:outcomeId>545e6f4fafea23.57082237</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>We have published 3 papers on shearflow induced structural changes in proteins, with 36 citations to date. A conference symposium invitation (in Shanghai) came directly from this work.
This work was also one of the reasons why UCB Pharma supported a recent CASE srtudentship as it relates to issues they are interested in solving in biopharmaceutical drug formulation.</gtr:description><gtr:firstYearOfImpact>2009</gtr:firstYearOfImpact><gtr:id>275C7621-6CD4-42DD-8F64-DD1AFD274578</gtr:id><gtr:impactTypes><gtr:impactType>Societal,Economic</gtr:impactType></gtr:impactTypes><gtr:outcomeId>545fcbed355456.48555631</gtr:outcomeId><gtr:sector>Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>We have found the first relationships between protein size, structural composition and stability of proteins under the effects of shear forces. These parameters are important for future design of more stable protein pharmaceuticals.
We also recorded the earliest onset of fibrils in a flowing solution, improving our awareness of how easily this unwanted process can occur.</gtr:description><gtr:exploitationPathways>Improving the stability of protein pharmaceuticals requires understanding the 'molecular rules' which govern how aggregation is induced in flowing fluids. The pharmaceutical sector is currently trying to understand these rules with the aim of taking these factors into account in future designs of modifying proteins to improve their stability.</gtr:exploitationPathways><gtr:id>0882067B-4595-4CFE-AEA9-F2E157E82058</gtr:id><gtr:outcomeId>545f949d959653.84012754</gtr:outcomeId><gtr:sectors><gtr:sector>Agriculture, Food and Drink,Healthcare,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>8E10E75C-2681-4E41-A34C-77FDC363ECCB</gtr:id><gtr:title>Raman Spectroscopy And Chemometrics To Investigate Time Dependent Physical Changes Of Insulin In Shear Stress Conditions</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/342d0a22e0ba464e90a486379e740647"><gtr:id>342d0a22e0ba464e90a486379e740647</gtr:id><gtr:otherNames>Webster G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>doi_53d0360363920659</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F93A6819-A86C-4EBE-B445-06F1BC4E23FB</gtr:id><gtr:title>Susceptibility of Different Proteins to Flow-Induced Conformational Changes Monitored with Raman Spectroscopy</gtr:title><gtr:parentPublicationTitle>BIOPHYSICAL JOURNAL</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc9dec4c51e10554ca44ae820a462fed"><gtr:id>fc9dec4c51e10554ca44ae820a462fed</gtr:id><gtr:otherNames>Lorna Ashton (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>r_6043749086035afdd4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8474F552-E99D-417B-95BA-63181755D82F</gtr:id><gtr:title>Investigation of polypeptide conformational transitions with two-dimensional Raman optical activity correlation analysis, applying autocorrelation and moving window approaches.</gtr:title><gtr:parentPublicationTitle>Applied spectroscopy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9075839413e99b20c7cdecc34f6bfc83"><gtr:id>9075839413e99b20c7cdecc34f6bfc83</gtr:id><gtr:otherNames>Ashton L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0003-7028</gtr:issn><gtr:outcomeId>doi_53d0800805ad7c3e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>43BDC680-8692-4579-A0EC-94EF6E4663DD</gtr:id><gtr:title>Detecting the early onset of shear-induced fibril formation of insulin in situ.</gtr:title><gtr:parentPublicationTitle>The journal of physical chemistry. B</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c8c4dcfb9cfbcdf771e212a7ad31c857"><gtr:id>c8c4dcfb9cfbcdf771e212a7ad31c857</gtr:id><gtr:otherNames>Webster GT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1520-5207</gtr:issn><gtr:outcomeId>doi_53d0190190f4f71c</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8439364A-4968-4F9B-A421-359DA89B9E4E</gtr:id><gtr:title>Shear-induced unfolding of lysozyme monitored in situ.</gtr:title><gtr:parentPublicationTitle>Biophysical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9075839413e99b20c7cdecc34f6bfc83"><gtr:id>9075839413e99b20c7cdecc34f6bfc83</gtr:id><gtr:otherNames>Ashton L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-3495</gtr:issn><gtr:outcomeId>doi_53cfe7fe70dcc962</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">EP/F007922/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>60EBB420-734E-4DB5-B0F2-65A1115A27F8</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Chemical synthesis</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>6723A70B-A523-40AB-9740-B6AD2A0677B7</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Medical &amp; health interface</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>FB535BD0-E265-4C0A-8532-32DCB83A3951</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Tools, technologies &amp; methods</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>0B9701E7-D17F-4963-82DA-B3926A65B50A</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Biological &amp; Medicinal Chem.</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>E4D49DD8-E515-4246-8886-C9E048C0E565</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Rheology</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>195B48B4-2BC5-4DEB-BA1A-323A90D8730D</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Tissue engineering</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>